New Coating for Urinary Intermittent Catheters

Coloplast A/S32 enrolled

Overview

The goal is to confirm, that the newly developed coating is non-inferior to the comparator with respect to the overall discomfort of the catheterisation (assessed by participant). Participants will attend 3 study site visits and will be catheterised by a HCP at visit 1 and 2 with one of the two catheters in randomisation order. Urine samples will be collected pre- and post catheterisation for assessments.

The primary objective of the study is to confirm that the newly developed investigational coating is non-inferior to the comparator coating with respect to the overall discomfort of catheterisation. The investigational device is a ready-to-use, sterile, hydrophilic-coated Nelaton male catheter for intermittent catheterisation and based on the standard SpeediCath® male intermittent catheter with a difference in the composition on the coating. The study is a double-blinded, randomized, crossover study including 32 randomized healthy male volunteers. The total study duration for the individual subject will be between 4-21 days and consists of 3 site visits V0, V1 and V2, and V0 andV1 can be combined At V1 and V2 the subjects will be catheterized in a hospital setting by a health care professional, with one of the two catheters in a randomized order. Subject will be asked to assess the overall discomfort of the catheterisation on VAS.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

Conditions

Retention, Urinary

Interventions

SpeediCath® Standard male new coatingDEVICE

Intermittent catheterization through the urethra draining the bladder, using SpeediCath® Standard male new coating CH12 by HCP

SpeediCath® Standard maleDEVICE

Intermittent catheterization through the urethra draining the bladder, using SpeediCath® Standard male CH 12 by HCP

Eligibility

Sex: MALEMin age: 18 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: 1. Has given written informed consent 2. Is at least 18 years old 3. Has full legal capacity 4. Has self-assessed intact male anatomy with no abnormalities or disease of the lower urinary tract or any surgical procedures performed in the lower urinary tract 5. Is able (assessed by investigator) and willing to adhere to study procedures during study duration. 6. Is able to refrain from using analgesics up to 24 hours prior to catheterisation visits 7. Is negative for haematuria, measured by urine dipstick test of erythrocytes Exclusion Criteria: 1. Is participating in any other clinical investigation during this investigation, which could affect the results of this investigation, as assessed by investigator. 2. Has previously been randomized in this investigation. 3. Has known hypersensitivity towards any of the devices used in the investigation 4. Is currently experiencing symptoms associated with UTI, as assessed by investigator. 5. Has known impaired sensation of the urethra

Locations (1)

Department of Urology, Rigshospitalet

Copenhagen, Denmark

Outcomes

Primary Outcomes

The Overall Discomfort During Catheterization Was Measured by VAS on a 10 cm Scale Ranging From "no Discomfort" (0 cm) to "Worst Possible Discomfort" (10 cm) Caused by the Catheter.

This endpoint was assessed by the subject immediately after completed catheterization, by setting a vertical line to indicate their experience of the overall catheterization.

Time frame: Immediately after the procedure

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.